RY 159.49 -2.2493% SHOP 134.86 0.6944% TD 83.2 -1.9562% ENB 61.17 -0.7464% BN 72.21 -0.6193% TRI 248.33 -0.9848% CNQ 41.395 1.1855% CP 105.84 -1.3791% CNR 137.8 -2.766% BMO 138.07 -2.1058% BNS 68.475 -0.9188% CSU 4745.1499 -1.1427% CM 79.7 -0.846% MFC 41.195 -0.0364% ATD 69.58 -2.6172% NGT 62.81 2.5804% TRP 66.74 -0.015% SU 50.92 -1.2029% WCN 266.23 -0.9598% L 186.93 -3.0647%
Last update at 2025-03-11T20:25:00Z
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Tue 11 Mar 25, 09:03 AMModerna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges
Mon 10 Mar 25, 12:52 AM3 CEOs Just Spent Millions Buying Their Beaten-Down Stock
Sun 09 Mar 25, 07:00 AMModerna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction
Fri 07 Mar 25, 05:42 PMBiotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
Thu 06 Mar 25, 08:00 PMHere's Why Moderna Stock Soared 16% on Wednesday
Thu 06 Mar 25, 02:13 PMWhy Moderna, Inc. (MRNA) Went Up on Wednesday
Thu 06 Mar 25, 12:55 PMWhy Moderna Stock Zoomed Nearly 16% Higher on Wednesday
Wed 05 Mar 25, 10:59 PMThe Dow surges 500 points as Trump hands out some tariff relief
Wed 05 Mar 25, 09:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 9575.00M | 13285.00M | -744.51300M | -514.71600M | -384.40800M |
| Minority interest | - | - | - | - | - |
| Net income | 8362.00M | 12202.00M | -747.06400M | -514.02100M | -384.73400M |
| Selling general administrative | 1132.00M | 567.00M | 188.27M | 109.62M | 94.25M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13847.00M | 15119.00M | 266.56M | 48.04M | 135.07M |
| Reconciled depreciation | 348.00M | 232.00M | 31.25M | 31.02M | 24.86M |
| Ebit | 9420.00M | 13064.00M | -794.39500M | -576.74100M | -438.12800M |
| Ebitda | 9768.00M | 13296.00M | -763.14400M | -545.72000M | -413.26600M |
| Depreciation and amortization | 348.00M | 232.00M | 31.25M | 31.02M | 24.86M |
| Non operating income net other | 155.00M | -11.00000M | 18.63M | 31.00M | 28.86M |
| Operating income | 9420.00M | 13296.00M | -763.14400M | -545.72000M | -413.26600M |
| Other operating expenses | 9843.00M | 4440.00M | 1037.63M | 593.76M | 535.78M |
| Interest expense | 29.00M | 18.00M | 9.89M | 6.61M | 0.00000M |
| Tax provision | 1213.00M | 1083.00M | 2.55M | -0.69500M | 0.33M |
| Interest income | 200.00M | 18.00M | 24.71M | 38.53M | 27.02M |
| Net interest income | 200.00M | 18.00M | 14.83M | 31.92M | 27.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1213.00M | 1083.00M | 2.55M | -0.69500M | 0.33M |
| Total revenue | 19263.00M | 17736.00M | 274.49M | 48.04M | 122.51M |
| Total operating expenses | 4427.00M | 1823.00M | 1029.70M | 593.76M | 535.78M |
| Cost of revenue | 5416.00M | 2617.00M | 7.93M | 496.31M | -12.55600M |
| Total other income expense net | 155.00M | -11.00000M | 18.63M | 31.00M | 1.83M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 8362.00M | 12202.00M | -747.06400M | -514.02100M | -384.73400M |
| Net income applicable to common shares | 8362.00M | 12202.00M | -747.06400M | -514.02100M | -401.85700M |
| Preferred stock and other adjustments | - | - | - | - | 17.12M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 18426.00M | 25858.00M | 24669.00M | 7336.75M | 1589.42M |
| Intangible assets | 44.00M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 88.00M | 1195.00M | 55.00M | -405.63100M | 887.90M |
| Total liab | 4572.00M | 6735.00M | 10524.00M | 4775.38M | 414.61M |
| Total stockholder equity | 13854.00M | 19123.00M | 14145.00M | 2561.38M | 1174.81M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1902.00M | 2202.00M | 2362.00M | 33.66M | 5.06M |
| Common stock | - | - | -857.00000M | 0.04M | 0.03M |
| Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.04M | 0.03M |
| Retained earnings | 13606.00M | 18320.00M | 9958.00M | -2243.51800M | -1496.45400M |
| Other liab | - | 808.00M | 691.00M | 179.27M | 139.13M |
| Good will | 52.00M | - | - | - | - |
| Other assets | - | 1928.00M | 7383.00M | 741.98M | 12.72M |
| Cash | 2907.00M | 3205.00M | 6848.00M | 2623.85M | 235.88M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3015.00M | 4923.00M | 9128.00M | 4388.81M | 143.12M |
| Current deferred revenue | 568.00M | 2038.00M | 6253.00M | 3867.19M | 63.31M |
| Net debt | -1664.00000M | -2005.00000M | -5932.00000M | -2416.55500M | -103.51200M |
| Short term debt | 25.00M | 196.00M | 211.00M | 469.59M | 67.65M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1243.00M | 1200.00M | 916.00M | 207.29M | 132.36M |
| Other stockholder equity | 371.00M | 1173.00M | 4211.00M | 4801.85M | 2669.43M |
| Property plant equipment | - | 2139.00M | 1383.00M | 387.09M | 287.91M |
| Total current assets | 10325.00M | 13431.00M | 17570.00M | 6297.88M | 1262.99M |
| Long term investments | 4743.00M | 8318.00M | 6843.00M | 638.85M | 159.99M |
| Net tangible assets | - | 19123.00M | 14145.00M | 2561.38M | 1174.81M |
| Short term investments | 5697.00M | 6697.00M | 3879.00M | 1983.76M | 867.12M |
| Net receivables | 1081.00M | 1385.00M | 3296.00M | 1410.53M | 16.30M |
| Long term debt | - | - | - | - | - |
| Inventory | 202.00M | 949.00M | 1441.00M | 46.53M | -904.19300M |
| Accounts payable | 520.00M | 487.00M | 302.00M | 18.36M | 7.09M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -123.00000M | -370.00000M | -24.00000M | 3.00M | 1.80M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 18320.00M | 9958.00M | -2243.51800M | -1500.00000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 523.00M | 988.00M | 46.00M | 12.93M | -121.46100M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 8101.00M | 12427.00M | 7099.00M | 1038.87M | 326.44M |
| Capital lease obligations | 1243.00M | 1004.00M | 916.00M | 207.29M | 132.36M |
| Long term debt total | - | - | - | - | 38.69M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -5176.00000M | -8239.00000M | -1604.48000M | 16.61M | -267.32800M |
| Change to liabilities | 112.00M | 2192.00M | 406.26M | -77.61400M | -40.54600M |
| Total cashflows from investing activities | -5176.00000M | -8523.00000M | -1671.92800M | -14.94500M | -372.47200M |
| Net borrowings | -184.00000M | -140.00000M | -6.21500M | 0.97M | 9.46M |
| Total cash from financing activities | -3448.00000M | -873.00000M | 2033.19M | 51.12M | 1226.84M |
| Change to operating activities | -992.00000M | 582.00M | 154.59M | 7.20M | 6.83M |
| Net income | 8362.00M | 12202.00M | -747.06400M | -514.02100M | -384.73400M |
| Change in cash | -3643.00000M | 4224.00M | 2388.24M | -422.79200M | 523.50M |
| Begin period cash flow | 6860.00M | 2636.00M | 247.70M | 670.49M | 134.86M |
| End period cash flow | 3217.00M | 6860.00M | 2635.93M | 247.70M | 658.36M |
| Total cash from operating activities | 4981.00M | 13620.00M | 2026.97M | -458.96800M | -330.86500M |
| Issuance of capital stock | 0.00000M | 0.00000M | 1852.72M | 0.00000M | 1224.14M |
| Depreciation | 348.00M | 232.00M | 31.25M | 31.02M | 24.86M |
| Other cashflows from investing activities | -40.00000M | -30.00000M | -30.00000M | 16.61M | 0.62M |
| Dividends paid | - | -124.00000M | -7.04000M | - | - |
| Change to inventory | 492.00M | -1394.00000M | -46.52700M | 7.20M | 4.41M |
| Change to account receivables | 1790.00M | -1784.00000M | -1385.19100M | 7.22M | 0.83M |
| Sale purchase of stock | -3329.00000M | -857.00000M | 7.04M | 2.89M | -8.18200M |
| Other cashflows from financing activities | -184.00000M | 124.00M | 186.68M | 0.97M | 674.17M |
| Change to netincome | -305.00000M | -176.00000M | 155.54M | 81.44M | 73.46M |
| Capital expenditures | 400.00M | 284.00M | 67.45M | 31.55M | 105.77M |
| Change receivables | 1790.00M | -1784.00000M | -1385.19100M | 7.22M | 0.83M |
| Cash flows other operating | -5849.00000M | 2294.00M | 3602.52M | 16.73M | -2.86900M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -3643.00000M | 4224.00M | 2388.24M | -422.79200M | 523.50M |
| Change in working capital | -3455.00000M | 990.00M | 2577.05M | -53.66400M | -42.58300M |
| Stock based compensation | 226.00M | 142.00M | 93.02M | 81.12M | 72.56M |
| Other non cash items | 59.00M | 372.00M | 62.29M | -3.42600M | -0.97500M |
| Free cash flow | 4581.00M | 13336.00M | 1959.52M | -490.52200M | -436.63100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRNA Moderna Inc |
-2.2 6.12% | 33.76 | - | 32.47 | 5.88 | 2.91 | 4.87 | -10.0256 |
| NVO Novo Nordisk A/S |
-0.84 1.06% | 78.11 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.23 1.55% | 78.25 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-11.67 2.33% | 488.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-26.67 3.58% | 718.16 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
200 Technology Square, Cambridge, MA, United States, 02139
| Name | Title | Year Born |
|---|---|---|
| Dr. Noubar B. Afeyan Ph.D. | Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board | 1963 |
| Mr. Stephane Bancel | CEO & Director | 1973 |
| Dr. Stephen Hoge M.D. | Pres | 1976 |
| Ms. Shannon Thyme Klinger | Chief Legal Officer & Corp. Sec. | 1971 |
| Mr. Juan Andres | Pres of Strategic Partnerships & Enterprise Expansion | 1965 |
| Mr. James M. Mock | Chief Financial Officer | 1977 |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer | NA |
| Dr. John V. W. Reynders Ph.D. | Chief Information Officer | NA |
| Dr. Melissa J. Moore Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | NA |
| Ms. Lavina Talukdar CFA | Sr. VP & Head of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...